Franchette W. P. J. van Den Berkmortel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Franchette W. P. J. van Den Berkmortel has a total of 211 co-authors. Here are the top co-authors by number of shared publications:
- Ellen Kapiteijn
Leiden University Medical Center, Leiden, The Netherlands
18 shared publications - John B. A. G. Haanen
The Netherlands Cancer Institute
17 shared publications - Karlijn P. M. Suijkerbuijk
Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CG Utrecht, the Netherlands
17 shared publications - Geke A. P. Hospers
Department of Medical Oncology, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands
15 shared publications - Djura Piersma
Department of Internal Medicine, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ Enschede, The Netherlands
14 shared publications - Marye Boers-Sonderen
Department of Medical Oncology, Radboud University Medical Center, Geert Grooteplein Zuid 10, Nijmegen 6525 GA, the Netherlands
14 shared publications
Latest Publications
- Open Access
- 21 June 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 244, 116889
Response and survival in unresectable in-transit metastatic melanoma according to treatment strategy
- 21 June 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 244, 116889
Open AccessResponse and survival in unresectable in-transit metastatic melanoma according to treatment strategy
- Open Access
- 25 May 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 242, 116831
AI-based histopathology analysis predicts checkpoint inhibitor response in advanced melanoma and identifies patterns associated with response
- 25 May 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 242, 116831
Open AccessAI-based histopathology analysis predicts checkpoint inhibitor response in advanced melanoma and identifies patterns associated with response
- Open Access
Associations between spatial distribution of immune cell subsets and clinical outcomes in patients with advanced melanoma treated with immune checkpoint inhibitors: results from the PUMA challenge
Patients with advanced melanoma are treated with immune checkpoint inhibitors (ICIs), yet less than 50% of patients achieve a durable response while all patients are exposed to the risk of severe side effects. Tumor-infiltrating lymphocytes (TILs) in pathology images are associated with ICI outcomes, but manual assessment is subjective. In addition, the predictive value of other immune cell subsets, including plasma cells, neutrophils, histiocytes, and melanophages, remains unclear. We organized the Panoptic segmentation of nUclei and tissue in advanced MelanomA (PUMA) challenge to evaluate whether the spatial localization of TILs and other immune cell subsets on melanoma H&E slides collected before start of treatment was associated with treatment outcomes. Algorithm performance was evaluated on a hidden test set, after which top-ranked algorithms were applied to pre-treatment metastatic whole-slide images from a large, multicenter cohort of patients with advanced melanoma treated with first-line ICIs ( n =1102). Automatically quantified tissue features and immune cell subsets were then associated with clinical outcomes. Top-performing algorithms improved detection of immune cell subsets, although accuracy for rare classes remained limited. Across challenge participants, TIL density showed the most consistent association with treatment response and survival. Associations for stromal TILs were weaker, while plasma cells, histiocytes, melanophages, neutrophils, necrosis and blood vessels did not show independent associations with outcomes. Overall, the results from the PUMA challenge improved the state of the art of immune cell detection in melanoma histopathology and show that intra-tumoral lymphocytes are the immune cell subset most consistently associated with treatment response and survival. Highlights: We organized the first melanoma-specific tissue and nuclei segmentation competition Winning algorithms were applied to 1102 whole-slide images for biomarker analysis Intra-tumoral TILs were associated with response to immune checkpoint inhibitors Other immune cell subsets showed no independent association with treatment outcomes Tissue segmentation on WSIs was limited by low heterogeneity in training data. Graphical
Open AccessAssociations between spatial distribution of immune cell subsets and clinical outcomes in patients with advanced melanoma treated with immune checkpoint inhibitors: results from the PUMA challenge
Patients with advanced melanoma are treated with immune checkpoint inhibitors (ICIs), yet less than 50% of patients achieve a durable response while all patients are exposed to the risk of severe side effects. Tumor-infiltrating lymphocytes (TILs) in pathology images are associated with ICI outcomes, but manual assessment is subjective. In addition, the predictive value of other immune cell subsets, including plasma cells, neutrophils, histiocytes, and melanophages, remains unclear. We organized the Panoptic segmentation of nUclei and tissue in advanced MelanomA (PUMA) challenge to evaluate whether the spatial localization of TILs and other immune cell subsets on melanoma H&E slides collected before start of treatment was associated with treatment outcomes. Algorithm performance was evaluated on a hidden test set, after which top-ranked algorithms were applied to pre-treatment metastatic whole-slide images from a large, multicenter cohort of patients with advanced melanoma treated with first-line ICIs ( n =1102). Automatically quantified tissue features and immune cell subsets were then associated with clinical outcomes. Top-performing algorithms improved detection of immune cell subsets, although accuracy for rare classes remained limited. Across challenge participants, TIL density showed the most consistent association with treatment response and survival. Associations for stromal TILs were weaker, while plasma cells, histiocytes, melanophages, neutrophils, necrosis and blood vessels did not show independent associations with outcomes. Overall, the results from the PUMA challenge improved the state of the art of immune cell detection in melanoma histopathology and show that intra-tumoral lymphocytes are the immune cell subset most consistently associated with treatment response and survival. Highlights: We organized the first melanoma-specific tissue and nuclei segmentation competition Winning algorithms were applied to 1102 whole-slide images for biomarker analysis Intra-tumoral TILs were associated with response to immune checkpoint inhibitors Other immune cell subsets showed no independent association with treatment outcomes Tissue segmentation on WSIs was limited by low heterogeneity in training data. Graphical
- Open Access
- 25 October 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 231, 116051
Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial
- 25 October 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 231, 116051
Open AccessHealth economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial
- Open Access
- 24 October 2025
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 176 (1) , 1-10
Clinical predictors of pseudoprogression in glioblastoma: a retrospective cohort analysis
Purpose: Distinguishing pseudoprogression (PsP) from true progression (TP) in glioblastoma (GBM) remains a diagnostic challenge, yet is essential for guiding treatment and counseling prognosis. This study retrospectively assessed the incidence, clinical predictors, and survival impact of PsP compared to TP. Methods: Patients with surgically treated GBM and postoperative (chemo)radiotherapy in two Dutch hospitals (2006–2021) were included. Reports of magnetic resonance imaging (MRI) scans performed 4 months post-radiotherapy and at 3-month intervals, as well as reports of MRI scans prompted by neurological decline, were evaluated for PsP, TP, or mixed response (MR). Associations with clinical, tumor, and treatment characteristics and overall survival (OS) were analyzed. Results: Of 424 GBM patients, 175 were eligible for PsP analysis. The incidence of PsP was 29.1%, and PsP was associated with longer OS (median 16.6 months, 95% CI 12.0–21.2) compared to MR (14.1 months, 95% CI 11.1–17.2) and TP (11.6 months, 95% CI 10.0–13.2; p = 0.010). However, PsP occurring < 4 months after chemoradiotherapy was linked to shorter OS (11.3 months) than PsP > 4 months (17.4 months; p = 0.027). Male sex was significantly associated with outcome in univariate analysis, showing a trend toward significance in multivariate analysis. Treatment completion remained significant only in the multivariate model. Conclusion: PsP is associated with improved survival compared to TP, though early-onset PsP portends poorer outcomes. None of the evaluated factors were a significant predictor of PsP in both univariate and multivariate analyses. Future research should focus on validating molecular markers, and refining PsP definitions using standardized criteria.
- 24 October 2025
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 176 (1) , 1-10
Open AccessClinical predictors of pseudoprogression in glioblastoma: a retrospective cohort analysis
Purpose: Distinguishing pseudoprogression (PsP) from true progression (TP) in glioblastoma (GBM) remains a diagnostic challenge, yet is essential for guiding treatment and counseling prognosis. This study retrospectively assessed the incidence, clinical predictors, and survival impact of PsP compared to TP. Methods: Patients with surgically treated GBM and postoperative (chemo)radiotherapy in two Dutch hospitals (2006–2021) were included. Reports of magnetic resonance imaging (MRI) scans performed 4 months post-radiotherapy and at 3-month intervals, as well as reports of MRI scans prompted by neurological decline, were evaluated for PsP, TP, or mixed response (MR). Associations with clinical, tumor, and treatment characteristics and overall survival (OS) were analyzed. Results: Of 424 GBM patients, 175 were eligible for PsP analysis. The incidence of PsP was 29.1%, and PsP was associated with longer OS (median 16.6 months, 95% CI 12.0–21.2) compared to MR (14.1 months, 95% CI 11.1–17.2) and TP (11.6 months, 95% CI 10.0–13.2; p = 0.010). However, PsP occurring < 4 months after chemoradiotherapy was linked to shorter OS (11.3 months) than PsP > 4 months (17.4 months; p = 0.027). Male sex was significantly associated with outcome in univariate analysis, showing a trend toward significance in multivariate analysis. Treatment completion remained significant only in the multivariate model. Conclusion: PsP is associated with improved survival compared to TP, though early-onset PsP portends poorer outcomes. None of the evaluated factors were a significant predictor of PsP in both univariate and multivariate analyses. Future research should focus on validating molecular markers, and refining PsP definitions using standardized criteria.
- Open Access
- 30 July 2025
- Published by Elsevier in Clinical Breast Cancer
- Vol. 25 (7) , 704-713.e3
Receptor Discordance During the Treatment Course of Patients With Metastatic Breast Cancer: Results From the SONABRE Registry
- 30 July 2025
- Published by Elsevier in Clinical Breast Cancer
- Vol. 25 (7) , 704-713.e3
Open AccessReceptor Discordance During the Treatment Course of Patients With Metastatic Breast Cancer: Results From the SONABRE Registry
- Open Access
AI-detected tumor-infiltrating lymphocytes for predicting outcomes in anti-PD1 based treated melanoma
Importance: Easy and accessible biomarkers to predict response to immune checkpoint inhibition (ICI)-treated melanoma are limited. Objective: To evaluate artificial intelligence (AI) detected tumor-infiltrating lymphocytes (TILs) on pretreatment melanoma metastases as a biomarker for response and survival in ICI-treated patients. Design: Multicenter cohort study including patients with advanced melanoma treated with first-line anti-PD1 ± anti-CTLA4 between 2016 and 2023. Median follow-up was 36.3 months. Setting: 11 melanoma treatment centers in the Netherlands. Participants: 1,202 patients with advanced cutaneous melanoma. Exposure: All patients received first-line anti-PD1 ± anti-CTLA4. Main Outcome(s) and Measure(s): The percentage of TILs inside manually annotated tumor area in H&E stained pretreatment metastases was determined using the Hover-NeXt model trained and evaluated on an independent melanoma dataset containing 166,718 pathologist-verified manually annotated cells. The primary outcome was objective response rate (ORR); secondary outcomes were progression-free survival (PFS) and overall survival (OS). Correlation with manual TILs, scored according to the guidelines stated by the immune-oncology working group, was evaluated with Spearman correlation coefficients. Logistic regression and Cox proportional regression were conducted, adjusted for age, sex, disease stage, ICI type, BRAF status, brain metastases, LDH level, and performance status. Results: Metastatic melanoma specimens were available for 1,202 patients, of whom 423 received combination therapy. Median TIL percentage was 9.9% (range 0.3% - 69.4%). A 10% increase in TILs was associated with increased ORR (adjusted OR 1.40 [95% 1.23-1.59]), PFS (adjusted HR 0.85 [95% CI 0.79 – 0.92]) and OS (adjusted HR 0.83 [95% CI 0.76 – 0.91]. Results were consistent for both patients treated with anti-PD1 monotherapy and combination treatment with anti-PD1 plus anti-CTLA4. When comparing manual TIL scoring with AI-detected TILs, associations with response and survival were consistently stronger for AI-detected TILs. Conclusions and Relevance: In patients with advanced melanoma, higher levels of AI-detected TILs on pre-treatment H&E slides were independently associated with improved ICI response and survival. Given the accessibility of TIL scoring on routine histology, TILs may serve as a predictive biomarker for ICI outcomes. To facilitate broader validation, the Hover-NeXt architecture and model weights are publicly available. Key points: Question: What is the predictive value of artificial intelligence-detected tumor-infiltrating lymphocytes (TILs) for clinical outcomes in patients with advanced melanoma receiving first-line immune checkpoint inhibition? Findings: In this multicenter cohort of 1202 patients, TILs in pretreatment metastases were quantified using a melanoma-specific publicly available AI model trained on an independent dataset. A 10% increase was associated with response (aOR 1.40 [95% CI 1.23–1.59]), progression-free survival (aHR 0.85 [95% CI 0.79–0.92]), and overall survival (aHR 0.83 [95% CI 0.76–0.91]). Associations were independent of clinical predictors. Meaning: AI-detected TILs in pretreatment melanoma metastases independently correlate with response and survival.
Open AccessAI-detected tumor-infiltrating lymphocytes for predicting outcomes in anti-PD1 based treated melanoma
Importance: Easy and accessible biomarkers to predict response to immune checkpoint inhibition (ICI)-treated melanoma are limited. Objective: To evaluate artificial intelligence (AI) detected tumor-infiltrating lymphocytes (TILs) on pretreatment melanoma metastases as a biomarker for response and survival in ICI-treated patients. Design: Multicenter cohort study including patients with advanced melanoma treated with first-line anti-PD1 ± anti-CTLA4 between 2016 and 2023. Median follow-up was 36.3 months. Setting: 11 melanoma treatment centers in the Netherlands. Participants: 1,202 patients with advanced cutaneous melanoma. Exposure: All patients received first-line anti-PD1 ± anti-CTLA4. Main Outcome(s) and Measure(s): The percentage of TILs inside manually annotated tumor area in H&E stained pretreatment metastases was determined using the Hover-NeXt model trained and evaluated on an independent melanoma dataset containing 166,718 pathologist-verified manually annotated cells. The primary outcome was objective response rate (ORR); secondary outcomes were progression-free survival (PFS) and overall survival (OS). Correlation with manual TILs, scored according to the guidelines stated by the immune-oncology working group, was evaluated with Spearman correlation coefficients. Logistic regression and Cox proportional regression were conducted, adjusted for age, sex, disease stage, ICI type, BRAF status, brain metastases, LDH level, and performance status. Results: Metastatic melanoma specimens were available for 1,202 patients, of whom 423 received combination therapy. Median TIL percentage was 9.9% (range 0.3% - 69.4%). A 10% increase in TILs was associated with increased ORR (adjusted OR 1.40 [95% 1.23-1.59]), PFS (adjusted HR 0.85 [95% CI 0.79 – 0.92]) and OS (adjusted HR 0.83 [95% CI 0.76 – 0.91]. Results were consistent for both patients treated with anti-PD1 monotherapy and combination treatment with anti-PD1 plus anti-CTLA4. When comparing manual TIL scoring with AI-detected TILs, associations with response and survival were consistently stronger for AI-detected TILs. Conclusions and Relevance: In patients with advanced melanoma, higher levels of AI-detected TILs on pre-treatment H&E slides were independently associated with improved ICI response and survival. Given the accessibility of TIL scoring on routine histology, TILs may serve as a predictive biomarker for ICI outcomes. To facilitate broader validation, the Hover-NeXt architecture and model weights are publicly available. Key points: Question: What is the predictive value of artificial intelligence-detected tumor-infiltrating lymphocytes (TILs) for clinical outcomes in patients with advanced melanoma receiving first-line immune checkpoint inhibition? Findings: In this multicenter cohort of 1202 patients, TILs in pretreatment metastases were quantified using a melanoma-specific publicly available AI model trained on an independent dataset. A 10% increase was associated with response (aOR 1.40 [95% CI 1.23–1.59]), progression-free survival (aHR 0.85 [95% CI 0.79–0.92]), and overall survival (aHR 0.83 [95% CI 0.76–0.91]). Associations were independent of clinical predictors. Meaning: AI-detected TILs in pretreatment melanoma metastases independently correlate with response and survival.
- Open Access
- 22 February 2025
- Published by SAGE Publications in Medical Decision Making
- Vol. 45 (3) , 302-317
Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma
Background: A decision model for patients with advanced melanoma to estimate outcomes of a wide range of treatment sequences is lacking. Objectives: To develop a decision model for advanced melanoma to estimate outcomes of treatment sequences in clinical practice with the aim of supporting decision making. The article focuses on methodology and long-term health benefits. Methods: A semi-Markov model with a lifetime horizon was developed. Transitions describing disease progression, time to next treatment, and mortality were estimated from real-world data (RWD) as a function of time since starting treatment or disease progression and patient characteristics. Transitions were estimated separately for melanoma with and without a BRAF mutation and for patients with favorable and intermediate prognostic factors. All transitions can be adjusted using relative effectiveness of treatments derived from a network meta-analysis of randomized controlled trials (RCTs). The duration of treatment effect can be adjusted to obtain outcomes under different assumptions. Results: The model distinguishes 3 lines of systemic treatment for melanoma with a BRAF mutation and 2 lines of systemic treatment for melanoma without a BRAF mutation. Life expectancy ranged from 7.8 to 12.0 years in patients with favorable prognostic factors and from 5.1 to 8.7 years in patients with intermediate prognostic factors when treated with sequences consisting of targeted therapies and immunotherapies. Scenario analyses illustrate how estimates of life expectancy depend on the duration of treatment effect. Conclusion: The model is flexible because it can accommodate different treatments and treatment sequences, and the duration of treatment effects and the transitions influenced by treatment can be adjusted. We show how using RWD and data from RCTs can harness advantages of both data sources, guiding the development of future decision models. Highlights: The model is flexible because it can accommodate different treatments and treatment sequences, and the duration of treatment effects as well as the transitions that are influenced by treatment can be adjusted. The long-term health benefits of treatment sequences depend on the place of different therapies within a treatment sequence. Assumptions about the duration of relative treatment effects influence the estimates of long-term health benefits. We show how the use of real-world data and data from randomized controlled trials harness the advantages of both data sources, guiding the development of future decision models.
- 22 February 2025
- Published by SAGE Publications in Medical Decision Making
- Vol. 45 (3) , 302-317
Open AccessDevelopment of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma
Background: A decision model for patients with advanced melanoma to estimate outcomes of a wide range of treatment sequences is lacking. Objectives: To develop a decision model for advanced melanoma to estimate outcomes of treatment sequences in clinical practice with the aim of supporting decision making. The article focuses on methodology and long-term health benefits. Methods: A semi-Markov model with a lifetime horizon was developed. Transitions describing disease progression, time to next treatment, and mortality were estimated from real-world data (RWD) as a function of time since starting treatment or disease progression and patient characteristics. Transitions were estimated separately for melanoma with and without a BRAF mutation and for patients with favorable and intermediate prognostic factors. All transitions can be adjusted using relative effectiveness of treatments derived from a network meta-analysis of randomized controlled trials (RCTs). The duration of treatment effect can be adjusted to obtain outcomes under different assumptions. Results: The model distinguishes 3 lines of systemic treatment for melanoma with a BRAF mutation and 2 lines of systemic treatment for melanoma without a BRAF mutation. Life expectancy ranged from 7.8 to 12.0 years in patients with favorable prognostic factors and from 5.1 to 8.7 years in patients with intermediate prognostic factors when treated with sequences consisting of targeted therapies and immunotherapies. Scenario analyses illustrate how estimates of life expectancy depend on the duration of treatment effect. Conclusion: The model is flexible because it can accommodate different treatments and treatment sequences, and the duration of treatment effects and the transitions influenced by treatment can be adjusted. We show how using RWD and data from RCTs can harness advantages of both data sources, guiding the development of future decision models. Highlights: The model is flexible because it can accommodate different treatments and treatment sequences, and the duration of treatment effects as well as the transitions that are influenced by treatment can be adjusted. The long-term health benefits of treatment sequences depend on the place of different therapies within a treatment sequence. Assumptions about the duration of relative treatment effects influence the estimates of long-term health benefits. We show how the use of real-world data and data from randomized controlled trials harness the advantages of both data sources, guiding the development of future decision models.
- Open Access
Adverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma Patients
Introduction: The difference in incidence and severity of anti-PD-1 therapy-related adverse events (irAEs) between adjuvant and advanced treated melanoma patients remains unclear, as no head-to-head studies have compared these groups. Methods: This multi-center cohort study analyzed melanoma patients treated with anti-PD-1 in adjuvant or advanced settings between 2015 and 2021. Comorbidities and ECOG performance status were assessed before treatment, and grade III-IV irAEs were monitored during treatment. Univariate and multivariate regression analyses were conducted to identify factors associated with irAE development. Results: A total of 1465 advanced melanoma patients and 908 resected melanoma patients received anti-PD-1 therapy. Adjuvant-treated patients were younger, with a median age of 63 years compared to 69 years in the advanced group (p < 0.01), and had a better ECOG performance status (p < 0.01). Comorbidities were seen more frequently in advanced melanoma patients than in those receiving adjuvant treatment, 76% versus 68% (p < 0.01). Grade III-IV irAEs occurred in 214 (15%) advanced treated patients and in 119 (13%) adjuvant-treated patients. Multivariate analysis showed an increased risk of severe irAE development with the presence of any comorbidity (adjusted OR 1.22, 95% CI 1.02–1.44) and ECOG status greater than 1 (adjusted OR 2.00, 95% CI 1.20–3.32). Adjuvant therapy was not associated with an increased risk of irAE development compared to advanced treatment (adjusted OR 0.95, 95% CI 0.74–1.21) after correcting for comorbidities and ECOG performance score. Anti-PD-1 therapy was halted due to toxicity (any grade irAE) more often in the adjuvant setting than in the advanced setting, 20% versus 15% (p < 0.01). Conclusions: Higher ECOG performance status and presence of any comorbidity were independently associated with an increased risk of Grade III-IV irAE in adjuvant and advanced treated melanoma patients. Patients treated in the adjuvant setting did not have an increased risk of developing severe irAEs compared to advanced melanoma patients. These findings are of clinical significance in consulting patients for adjuvant anti-PD-1 treatment.
Open AccessAdverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma Patients
Introduction: The difference in incidence and severity of anti-PD-1 therapy-related adverse events (irAEs) between adjuvant and advanced treated melanoma patients remains unclear, as no head-to-head studies have compared these groups. Methods: This multi-center cohort study analyzed melanoma patients treated with anti-PD-1 in adjuvant or advanced settings between 2015 and 2021. Comorbidities and ECOG performance status were assessed before treatment, and grade III-IV irAEs were monitored during treatment. Univariate and multivariate regression analyses were conducted to identify factors associated with irAE development. Results: A total of 1465 advanced melanoma patients and 908 resected melanoma patients received anti-PD-1 therapy. Adjuvant-treated patients were younger, with a median age of 63 years compared to 69 years in the advanced group (p < 0.01), and had a better ECOG performance status (p < 0.01). Comorbidities were seen more frequently in advanced melanoma patients than in those receiving adjuvant treatment, 76% versus 68% (p < 0.01). Grade III-IV irAEs occurred in 214 (15%) advanced treated patients and in 119 (13%) adjuvant-treated patients. Multivariate analysis showed an increased risk of severe irAE development with the presence of any comorbidity (adjusted OR 1.22, 95% CI 1.02–1.44) and ECOG status greater than 1 (adjusted OR 2.00, 95% CI 1.20–3.32). Adjuvant therapy was not associated with an increased risk of irAE development compared to advanced treatment (adjusted OR 0.95, 95% CI 0.74–1.21) after correcting for comorbidities and ECOG performance score. Anti-PD-1 therapy was halted due to toxicity (any grade irAE) more often in the adjuvant setting than in the advanced setting, 20% versus 15% (p < 0.01). Conclusions: Higher ECOG performance status and presence of any comorbidity were independently associated with an increased risk of Grade III-IV irAE in adjuvant and advanced treated melanoma patients. Patients treated in the adjuvant setting did not have an increased risk of developing severe irAEs compared to advanced melanoma patients. These findings are of clinical significance in consulting patients for adjuvant anti-PD-1 treatment.
- Open Access
- 13 June 2024
- Published by Elsevier in Immuno-Oncology and Technology
- Vol. 24, 100714
Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma
- 13 June 2024
- Published by Elsevier in Immuno-Oncology and Technology
- Vol. 24, 100714
Open AccessTumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma